Designed synthetic analogs of the α-helical peptide temporin-La with improved antitumor efficacies via charge modification and incorporation of the integrin αvβ3 homing domain

Journal of Peptide Science

Volumn 18, Issue 7, 2012, Pages 476-486

  Diao, Yuwen ^a   Han, Wenyu ^a   Zhao, Honglei ^a   Zhu, Seng ^a   Liu, Xiaohe ^a   Feng, Xin ^a   Gu, Jingmin ^a   Yao, Cuimei ^a   Liu, Shanshan ^a   Sun, Changjiang ^a   Pan, Fengguang ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Antimicrobial peptides; Antitumor activities; Bioinformatic analysis; Integrin v 3; Net charge

Indexed keywords

ANION; ANTIMICROBIAL CATIONIC PEPTIDE; ANTINEOPLASTIC AGENT; ARG GLY ASP TRIPEPTIDE LA; ARG GLY ASP TRIPEPTIDE LAS; ARGININE; POLYPEPTIDE ANTIBIOTIC AGENT; TEMPORIN LAS; TRIPEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ALPHA HELIX; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER CELL CULTURE; CELL KILLING; CELL MEMBRANE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; EXAMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RAT; SCANNING ELECTRON MICROSCOPE; STATIC ELECTRICITY;

ANTINEOPLASTIC AGENTS; CELL MEMBRANE; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTEGRIN ALPHAVBETA3; MODELS, MOLECULAR; OLIGOPEPTIDES; PROTEIN STRUCTURE, TERTIARY; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84862618399     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2420     Document Type: Article

References (44)

1. Maino DM, Tran S, Mehta F. Side effects of chemotherapeutic oculo-toxic agents: a review. Clin. Eye Vis. Care. 2000; 12: 113-117.
2. Verrills NM, Kavallaris M. Drug resistance mechanisms in cancer cells: a proteomics perspective. Curr. Opin. Mol. Ther. 2003; 5: 258-265.
3. Tan DS, Gerlinger M, Teh BT, Swanton C. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur. J. Cancer 2010; 46: 2166-2177.
4. Calcagno AM, Ambudkar SV. Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol. Biol. 2010; 596: 77-93.
5. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int. J. Cardiol. 2010; 144: 3-15.
6. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
7. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 2008; 1778: 357-375.
8. Wang KR, Zhang BZ, Zhang W, Yan JX, Li J, Wang R. Antitumor effects, cell selectivity and structure-activity relationship of a novel antimicrobial peptide polybia-MPI. Peptides 2008; 29: 963-968.
9. Wang C, Li HB, Li S, Tian LL, Shang DJ. Antitumor effects and cell selectivity of temporin-1CEa, an antimicrobial peptide from the skin secretions of the Chinese brown frog (Rana chensinensis). Biochimie 2012; 94: 434-441.
10. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ. In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides 2003; 24: 945-953.
11. Lienkamp K, Tew GN. Synthetic mimics of antimicrobial peptides-a versatile ring-opening metathesis polymerization based platform for the synthesis of selective antibacterial and cell-penetrating polymers. Chemistry 2009; 15: 11784-11800.
12. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63: 389-406.
13. Rathinakumar R, Walkenhorst WF, Wimley WC. Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J. Am. Chem. Soc. 2009; 131: 7609-7617.
14. He J, Anderson MH, Shi W, Eckert R. Design and activity of a 'dual-targeted' antimicrobial peptide. Int. J. Antimicrob. Agents 2009; 33: 532-537.
15. Jiang Z, Vasil AI, Hale J, Hancock RE, Vasil ML, Hodges RS. Effects of net charge and the number of positively charged residues on the biological activity of amphipathic α-helical cationic antimicrobial peptides. Adv. Exp. Med. Biol. 2009; 611: 561-562.
16. Hong SY, Park TG, Lee KH. The effect of charge increase on the specificity and activity of a short antimicrobial peptide. Peptides 2001; 22: 1669-1674.
17. Yamamoto N, Tamura A. Designed low amphipathic peptides with α-helical propensity exhibiting antimicrobial activity via a lipid domain formation mechanism. Peptides 2010; 31: 794-805.
18. Dathe M, Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta 1999; 1462: 71-87.
19. Iwasaki T, Ishibashi J, Tanaka H, Sato M, Asaoka A, Taylor D, Yamakawa M. Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 2009; 30: 660-668.
20. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin. Investig. Drugs 2006; 15: 933-946.
21. Dennison SR, Harris F, Bhatt T, Singh J, Phoenix DA. A theoretical analysis of secondary structural characteristics of anticancer peptides. Mol. Cell. Biochem. 2010; 333: 129-135.
22. Dobrzynska I, Szachowicz-Petelska B, Sulkowski S, Figaszewski Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem. 2005; 276: 113-119.
23. Yoon WH, Park HD, Lim K, Hwang BD. Effect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cells. Biochem. Biophys. Res. Commun. 1996; 222: 694-699.
24. Marquez M, Nilsson S, Lennartsson L, Liu Z, Tammela T, Raitanen M, Holmberg AR. Charge-dependent targeting: results in six tumor cell lines. Anticancer Res. 2004; 24: 1347-1351.
25. Han WY, Zhao RL, Han JY, Lei LC, Sun CJ, Feng X, Jiang LN, Qiao HW, Cai LJ. Molecular cloning of two novel temporins from Lithobates catesbeianus and studying of their antimicrobial mechanisms. Prog. Biochem. Biophys. 2009; 36: 1064-1070.
26. Wang Z, Wang G. APD: the Antimicrobial Peptide Database. Nucleic Acids Res. 2004; 32: D590-592.
27. Fauchère J, Pliska V. Hydrophobic parameters-pi of amino-acid side-chains from the partitioning of N-acetyl-amino-acid amides. Eur. J. Med. Chem. 1983; 8: 369-375.
28. Eisenberg D, Weiss RM, Terwilliger TC. The helical hydrophobic moment: a measure of the amphiphilicity of a helix. Nature 1982; 299: 371-374.
29. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982; 157: 105-132.
30. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, Hochstrasser DF. Protein identification and analysis tools in the ExPASy server. Methods Mol. Biol. 1999; 112: 531-552.
31. Tossi A, Sandri L, Giangaspero A. Amphipathic, α-helical antimicrobial peptides. Biopolymers 2000; 55: 4-30.
32. Gautier R, Douguet D, Antonny B, Drin G. heliquest: a web server to screen sequences with specific α-helical properties. Bioinformatics 2008; 24: 2101-2102.
33. Tamura K, Dudley J, Nei M, Kumar S. mega4: Molecular Evolutionary Genetics Analysis (mega) software version 4.0. Mol. Biol. Evol. 2007; 24: 1596-1599.
34. Deleage G, Combet C, Blanchet C, Geourjon C. antheprot: an integrated protein sequence analysis software with client/server capabilities. Comput. Biol. Med. 2001; 31: 259-267.
35. Kerwin SM. ChemBioOffice Ultra 2010 suite. J. Am. Chem. Soc. 2010; 132: 2466-2467.
36. Bignami GS. A rapid and sensitive hemolysis neutralization assay for palytoxin. Toxicon 1993; 31: 817-820.
37. Mangoni ML, Rinaldi AC, Di Giulio A, Mignogna G, Bozzi A, Barra D, Simmaco M. Structure-function relationships of temporins, small antimicrobial peptides from amphibian skin. Eur. J. Biochem. 2000; 267: 1447-1454.
38. Simmaco M, Mignogna G, Canofeni S, Miele R, Mangoni ML, Barra D. Temporins, antimicrobial peptides from the European red frog Rana temporaria. Eur. J. Biochem. 1996; 242: 788-792.
39. Carter HB, Coffey DS. Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. J. Urol. 1988; 140: 173-175.
40. Papo N, Shai Y. Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides 2003; 24: 1693-1703.
41. Liu S. Radiolabeled cyclic RGD peptides as integrin α(v)β(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug. Chem. 2009; 20: 2199-2213.
42. Dijkgraaf I, Beer AJ, Wester HJ. Application of RGD-containing peptides as imaging probes for αvβ3 expression. Front. Biosci. 2009; 14: 887-899.
43. Frochot C, Di Stasio B, Vanderesse R, Belgy MJ, Dodeller M, Guillemin F, Viriot ML, Barberi-Heyob M. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorine as novel photosensitizers for selective photodynamic activity. Bioorg. Chem. 2007; 35: 205-220.
44. Gibrat JF, Garnier J, Robson B. Further developments of protein secondary structure prediction using information theory. New parameters and consideration of residue pairs. J. Mol. Biol. 1987; 198(3): 425-443.